REDUCe 2 (REpeated Drainage in Untreatable Cirrhosis) Study
REDUCe 2 study is a NIHR HTA funded multicentre trial following on from the earlier feasibility REDUCe Study(Macken L et al, APT 2020). The REDUCe 2 study is a randomised controlled trial comparing palliative long-term abdominal drains vs. large volume paracentesis in patients with refractory ascites due to cirrhosis. Recruitment commences Sept/Oct 2022 and will continue until June 2026. The study will be conducted across 35 sites in England and Scotland. If you are interested in participating please contact the Chief Investigator Sumita Verma (email@example.com). The study abstract can be found by clicking on the link below.
CALIBRE - Carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis
CALIBRE re-opened on 5th January 2022
Trial Design: A multicentre randomised controlled, open-label, self-evident two-arm trial with internal pilot.
Aim: To investigate the clinical and cost-effectiveness of carvedilol versus variceal band ligation in patients with cirrhosis and medium to large oesophageal varices that have not bled.
Sample size: 2630 – CALIBRE is largest ever Phase III trial in cirrhosis.
Funding: NIHR HTA funded - £2.3m. Sponsor is University of Birmingham.
Recruitment: Over 4 years nationally. All acute NHS trusts and health boards in UK are potentially eligible
Primary end point: Any variceal bleeding within 1 year of randomisation. Full protocol has been published: https://bmjopengastro.bmj.com/content/6/1/e000290
For further information and details of how your site can participate in CALIBRE please contact firstname.lastname@example.org . The CALIBRE website provides full details: https://www.birmingham.ac.uk/research/bctu/trials/portfolio-v/CALIBRE/CALIBRE.aspx
Beta Blockers Or Placebo for Primary Prophylaxis of oesophageal varices (BOPPP)
This is a UK-wide multi-centre randomised controlled trial. It will address whether primary prophylaxis against future variceal haemorrhage with non-selective beta blockers is clinically and economically effective in patients with cirrhosis and small varices. The National Institute of Health Research Health Technology Assessment (NIHR: HTA) programme commissioned this research with funding secured of £2.3 million to consent, treat and follow up 1,200 patients at multiple hospitals across the UK. The trial is led by the Institute of Liver Sciences, Kings College Hospital and Kings College London Clinical Trials Unit. BOPPP will be one of the largest ever portal hypertension trials in this group of patients, and is currently (March 2020) being run at 24 UK-wide sites, with a further 25 sites being invited to open to recruitment over the next 6 months.
Please contact email@example.com for further information and for details of how your site can participate in BOPPP.
BOPPP Trial Manager: Joanne Leahy
Telephone: 020 3299 7142
Further information is also available in this link: Download BOPPP_Summary_Feb2020.pdf
ASEPTIC (Primary Antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis)
ASEPTIC is an NIHR HTA funded multi-centre trial to examine the efficacy of primary prophylaxis using the narrow spectrum antibiotic Co-Trimoxazole in patients with cirrhosis and ascites.
We are still looking for sites and the study will run for the next 4 years. Please contact the chief Investigator Alastair O’Brien via email a.o’firstname.lastname@example.org for more details.
For more information: Download ASEPTIC trial information for BSG and BASL.pdf.
Minimising Mortality from Alcoholic Hepatitis
The MRC Stratified Medicine application entitled ‘Minimising Mortality from Alcoholic Hepatitis’ will commence in April 2018 and will last for 5 years. The award was for £5M and will involve Imperial College (Mark Thursz, Harry Antonaides, Elaine Holmes), University of Birmingham (David Adams, Trish Lalor, Chris Weston), University College London (William Rosenberg), MRC Biostatistics Unit Cambridge (Paul Newcombe), University of Edinburgh (Stuart Forbes) and University of Plymouth (Ashwin Dhanda) as well as the 40 clinical sites recruiting patients.
Read more on the BSG website > here.